NGL Fine-Chem Ltd. (IN:NGLFINE)
:NGLFINE
Want to see IN:NGLFINE full AI Analyst Report?
NGLFINE Stock Chart & Stats
₹1427.00
₹2.30(0.13%)
At close: 4:00 PM EST
₹1427.00
₹2.30(0.13%)
Day’s Range― - ―
52-Week Range₹985.05 - ₹3,000.00
Previous CloseN/A
Volume1.22K
Average Volume (3M)156.00
Market Cap
₹16.68B
Enterprise Value₹17.32B
Total Cash (Recent Filing)₹637.29M
Total Debt (Recent Filing)₹882.03M
Price to Earnings (P/E)33.9
Beta0.94
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)33.49
Shares Outstanding6,178,024
10 Day Avg. Volume192
30 Day Avg. Volume156
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.86
Price to Sales (P/S)2.54
P/FCF Ratio-25.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained re-acceleration of revenue (22.6% in 2026) indicates recovering end-market demand and better commercial traction. Over 2–6 months this supports higher capacity utilization, revenue visibility and the potential to convert scale into steadier operating profits if the trend persists.
Improving ProfitabilityA near-doubling of net margin to ~9.6% signals the company is regaining pricing power or operating leverage. If maintained, improved margins bolster earnings quality and ROE, enabling reinvestment and dividend support over the medium term versus prior weaker margin years.
Manageable Leverage & ROE RecoveryModerate debt-to-equity (~0.33) with steadily growing equity and rising ROE (~14.6%) provides balance-sheet capacity for investment and cushions downside. This structural financial health supports funding of growth initiatives and reduces refinancing risk over the medium term.
Bears Say
Gross Margin CompressionA material gross margin decline (from ~50% to ~35%) erodes core profitability and suggests persistent cost, mix or pricing pressure. Such structural compression reduces earnings power and requires sustained remediation (pricing, cost cuts or higher-value product mix) to restore historical margins.
Weak Cash Conversion & Negative FCFConsistently negative free cash flow and poor cash conversion (OCF only ~26% of net income) mean reported profits do not translate into cash. Over months this constrains organic funding for capex, dividends or debt paydown, increasing reliance on external financing and execution risk.
Volatile Profitability Vs. Peak LevelsDespite recent improvement, profits and operating margins remain volatile and underperform peak historical levels. This points to uneven execution or cyclical exposure in the business model, raising the risk that short-term gains may not be durable without structural fixes.
NGL Fine-Chem Ltd. News
NGLFINE FAQ
What was NGL Fine-Chem Ltd.’s price range in the past 12 months?
NGL Fine-Chem Ltd. lowest stock price was ₹985.05 and its highest was ₹3000.00 in the past 12 months.
What is NGL Fine-Chem Ltd.’s market cap?
NGL Fine-Chem Ltd.’s market cap is ₹16.68B.
When is NGL Fine-Chem Ltd.’s upcoming earnings report date?
NGL Fine-Chem Ltd.’s upcoming earnings report date is Jul 31, 2026 which is in 62 days.
How were NGL Fine-Chem Ltd.’s earnings last quarter?
NGL Fine-Chem Ltd. released its earnings results on May 21, 2026. The company reported ₹21.83 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.83.
Is NGL Fine-Chem Ltd. overvalued?
According to Wall Street analysts NGL Fine-Chem Ltd.’s price is currently Overvalued.
Does NGL Fine-Chem Ltd. pay dividends?
NGL Fine-Chem Ltd. pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.13%. See more information on NGL Fine-Chem Ltd. dividends here
What is NGL Fine-Chem Ltd.’s EPS estimate?
NGL Fine-Chem Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NGL Fine-Chem Ltd. have?
NGL Fine-Chem Ltd. has 6,178,024 shares outstanding.
What happened to NGL Fine-Chem Ltd.’s price movement after its last earnings report?
NGL Fine-Chem Ltd. reported an EPS of ₹21.83 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.702%.
Which hedge fund is a major shareholder of NGL Fine-Chem Ltd.?
Currently, no hedge funds are holding shares in IN:NGLFINE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NGL Fine-Chem Ltd.
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
SMS Pharmaceuticals Limited
―
Senores Pharmaceuticals Ltd.
―